Sunrest Lifescience

Sunrest Lifescience LT Debt/Equity

The Long-Term Debt to Equity Ratio of Sunrest Lifescience (SUNREST.NS) as of Nov 5, 2026 is 0.35. In the previous year, Long-Term Debt to Equity Ratio was 0.24 — a change of 44.03% (higher).

LT Debt/Equity

0.35

YoY

44.03%

Last updated:

Long-Term Debt to Equity Ratio of Sunrest Lifescience is 2025 0.35 . Long-Term Debt to Equity Ratio of Sunrest Lifescience was 2024 0.24 . It decreases by 44.03% higher compared to the previous year.

The Sunrest Lifescience LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2021
7.86 INR
Jan 1, 2022
2.89 INR
Jan 1, 2023
0.64 INR
Jan 1, 2024
0.24 INR
Jan 1, 2025
0.35 INR
The Sunrest Lifescience LT Debt/Equity history
YEARLT Debt/EquityYoY
0.35+44.03%
0.24-61.93%
0.64-77.80%
2.89-63.27%
7.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunrest Lifescience Stock analysis

What does Sunrest Lifescience do? Sunrest Lifescience Ltd markets OTC generic pharmaceutical products manufactured by third party manufacturers. The company sells capsules, tablets, syrup, ointment, gel, mouth wash, solution, suspension, dry powders, and toothpaste. Its product portfolio includes Anti-Bacterial, Anti Diarrheal, Antifungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-inflammatory drugs. The company operates in Maharashtra, Gujarat, Madhya Pradesh, Orissa, and Rajasthan, selling to stockists who distribute products to chemist shops, dispensaries, and hospitals. Sunrest Lifescience Ltd targets domestic markets through third party manufacturers for OTC generic products. The firm's sales channels include stockists who supply chemist shops, dispensaries, and hospitals across multiple Indian states. The company's product range serves various health segments from anti-bacterial treatments to multivitamins and dental care. The company's revenue comes from the sale of OTC generic pharmaceutical products to stockists, who then distribute them to end consumers via chemist shops, dispensaries, and hospitals. Sunrest Lifescience Ltd focuses on domestic market distribution without direct retail presence, leveraging third party manufacturers for product supply. Sunrest Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunrest Lifescience stock

Long-Term Debt to Equity Ratio of Sunrest Lifescience is 0.35 in 2025.

Long-Term Debt to Equity Ratio of Sunrest Lifescience changed from 0.24 to 0.35, representing a 44.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Sunrest Lifescience since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Sunrest Lifescience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sunrest Lifescience

All Key Metrics — Sunrest Lifescience